AKR1A1 and allergic asthma: In summary, our studies demonstrated that the intranasal administration of SPL-334, a selective inhibitor of GSNOR among the alcohol dehydrogenase isozymes, limits eosinophilic inflammation, mucus production and airway hyperreactivity in a model of allergic asthma.